# INTAKE FORM COLLABORATION AGREEMENT THE UNIVERSITY OF TEXAS RIO GRANDE VALLEY

#### THIS IS NOT A COLLABORATION AGREEMENT

Information provided on this form will help the Office of Research Contract & Industry Agreements (CIA) develop an agreement to send to the Collaborator. Please complete and return to CIA at rcia@utrgv.edu.

## **UTRGV INVESTIGATOR INFORMATION**

UTRGV Requesting Investigator:	
Department:	Building & Room:
Email:	Phone:
Administrative Contact (if different from PI):	
Title:	Email:
COLLABO	PRATOR INFORMATION
Firm or Institution:	
Address:	
Primary Contact Name:	Title:
Email:	Phone:
Additional Contact (if different from Primary Contac	t):
Title:	Email:
PROJ	ECT INFORMATION
Project Title:	
Is this collaboration part of a funded project? Y	YES NO If YES, provide ARGO #:

Provide a brief project description and describe each party's contribution in this Collaboration (Please attach

abstract/protocol):

Page 1 of 5 10.13.2025

RESEARCH PLAN	YES	NO
Do you intend to publish your findings?		
If YES, are you willing to provide an advanced copy of the paper to Collaborator for review?		
Does the RESEARCH PLAN relate to or include an invention disclosed to UTRGV?  If YES, please provide Disclosure Date:		
Do Principal Investigators or other key investigators have significant financial interest or management interest in the collaborating company?		
If YES, is there an approved Conflict of Interest Management Plan in place?  (For more information, email: researchcompliance@utrgv.edu)		
Is there a likelihood of an invention resulting from Collaboration?  If YES, please attach a detailed description.		
Will Confidential Information be shared?		
Will the Collaboration involve a Collaborator from outside of the United States?		
Are there clearly defined deliverables and timelines for each party?  If YES, please attach a timeline or project management plan.		
Will this Collaboration result in the creation of new datasets or biorepositories?		
If YES, describe access, storage, and usage plans:		
Will the research output be made publicly available (open data repositories)?		
If YES, specify repository or platform to be used:		

The RESEARCH PLAN identified must have an approved study with a corresponding number for each of the activities checked. (Check all that apply)

TYPE OF STUDY	YES	NO	STUDY#	APPROVAL STATUS
Animal Use				
Human Subjects				
Recombinant DNA				
Biohazardous Agents				

Please attach an approval letter(s) with all other documents attached with application.

Page 2 of 5 10.13.2025

#### **MATERIAL TRANSFER INFORMATION**

Will there be an exchan	YES	NC			
If YES, indicate who will be providing MATERIAL.					
UTRGV	Collaborator	Both			

Describe the purpose of the MATERIAL. (Check all that apply)

The MATERIAL will be provided for the purpose of product testing and evaluation (i.e. testing and expression system) for the organization providing.
The MATERIAL is a tool, kit, or instrument that will be used in the conduct of research.
The MATERIAL is a reagent.
Progeny, unmodified derivatives, or descendant copies will be made from MATERIAL.
MATERIAL will be modified or will be used to produce modified derivatives.
Other, please explain in layman's terms:

	YES	NO
Is the MATERIAL patented or patent pending?		
Is the MATERIAL in clinical use?		
Will you be making any modifications to the MATERIAL?		
If YES, describe how?	I	I
Is MATERIAL from human cell line(s)?		
If YES, please attach documentation that the MATERIAL is pathogen free.		
Will the MATERIAL require reimbursement by the RECIPIENT for the cost of this MATERIAL or shipment of the MATERIAL?		

## **DEFINITIONS**

Progeny: Unmodified descendants from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.

Unmodified Derivatives: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the MATERIAL. Examples: subclones of unmodified cell lines, purified or fractionated subsets of the MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line supplied by the PROVIDER.

> Page 3 of 5 10.13.2025

#### **DATA TRANSFER INFORMATION**

Will there be an exchange of data? YES NO

If YES, who will be providing the data? UTRGV Collaborator Both

# Type of data (check all that apply):

De-identified data

Limited data set

Personally identifiable information – Common Rule Only

Personally identifiable information - HIPAA

Personally identifiable information – FERPA

## Does the project involve the use of data pertaining to human subjects? YES NO

## If YES, does the research meet the definition of human subjects research?

No. PI and/or IRB determined that project is not human subjects research.

Yes. (Indicate status of IRB protocol below):

IRB protocol has not been submitted yet.

IRB protocol review is pending.

Approved IRB.

# Data delivery method:

Electronically

By mail

Other, please describe:

## Describe the Data to be exchanged: (Include all the following details.)

- Type of data collection
- Data collection methods
- Data analysis plan

- Method on how data will be transferred.
- Method of disposition or archiving data after completion of the project.

Page 4 of 5 10.13.2025

# **OTHER CONSIDERATIONS**

# **ON-SITE VISITS**

IRB/IACUC approval letter(s)

Conflict of Interest Management Plan Any agreement(s) relating to this project.

Will the colla	boration involve	any on-site visits or physic	al presence	at either (	Collaborator's facilities or UTRGV?
YES	NO				
If YES, indicat	te location(s):	<b>Collaborator Facility</b>	UTRGV	OTHER:	
Purpose of vi	sit:				
Duration:					
IN-KIND CO	NTRIBUTIONS				
Will there be	any in-kind contr	ibutions provided by eithe	er party?	YES	NO
If YES, specif	y type (check all t	hat apply)			
	facilities eer Services				
To the best of	f my knowledge, t	he above information is tr	ue and corre	ct.	
Signature:		Date:			
UTRGV Invest					
Acknowledge	d without objecti	on.			
Signature:		Date:			
Department (					
		Date:			
Associate Dea	an for Research (in	itials)			
Attach the follo	<b>owing, if applicable</b> r Protocol	:			

If there are any questions regarding the agreement, please email rcia@utrgv.edu.

Page 5 of 5 10.13.25